Cirrhosis

From IDWiki
Revision as of 02:23, 27 November 2021 by Aidan (talk | contribs) ()
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Background

  • End-stage hepatic fibrosis with hepatic dysfunction

Epidemiology

  • 25% of Canadians have NAFLD

Etiology

JAMA Rational Clinical Exam

  • Ascites (LR+ 7.2)
  • Platelet count <160 (LR+ 6.3; LR- 0.29 if ≥160)
  • Spider nevi (LR+ 4.3)
  • Bonacini cirrhosis discriminant score >7 (LR+ 9.4)
  • Lok index <0.2 (LR- 0.09)
  • Absence of hepatomegaly (LR- 0.37)

Investigations

  • Lab abnormalities in liver failure, in order:
    • Decrease in platelets
    • Increase in bilirubin
    • Decrease in albumin
    • Increase in INR
  • Investigations for possible causes of cirrhosis include:
    • Liver ultrasound
    • Hepatitis B and C serologies
    • Ferritin and transferrin saturation, for hereditary hemochromatosis
    • Autoimmune serologies
      • ANA and anti-smooth muscle antibodies, for PSC and AIH
      • Anti-mitochondrial antibodies and anti-parietal cell antibodies, for PBC
      • Consider anti-LKM-1, for PSC
    • Quantitative immunoglobulins, for elevated IgM in PBC or hypergammaglobulinemia in AIH
    • Consider serum ceruloplasmin, for Wilson disease
    • Consider α-1 antitripsyin levels, for deficiency

Management

  • Decompensated
  • Ascites
    • Furosemide 40 and spironolactone 100 (max 160/400)
    • Serial therapeutic paracentesis
      • Small-volume (<4-5L) does not need albumin
      • Large-volume needs 6-8 g of 25% albumin per litre removed
    • Avoid indwelling drain
    • TIPS can be considered but precipitates encephalopathy
  • Prophylaxis/chronic
    • SBP: maybe?
    • Encephalopathy: no role for primary prophylaxis
    • Surveillance with upper endoscopy
    • Ultrasound q6mo for HCC

Preventative Care

Prognosis

  • Median survival 1.6 years after admission for decompensated cirrhosis